Aktis Oncology, Inc. (AKTS) compared with its closest peers (CYPH, MANE, RLMD, DMAC, NRXP). Peer set by Pharmaceutical Products; 10 comparable drugmakers. First-party data.
Cypherpunk Technologies, Veradermics, Relmada Therapeutics, DiaMedica Therapeutics, NRx Pharmaceuticals, PDS Biotechnology, Longeveron, RenovoRx, Oramed Pharmaceuticals and Sagimet Biosciences share Aktis Oncology's sub-industry, pharmaceutical makers.
| Company | Market Cap | P/E |
|---|---|---|
| Cypherpunk Technologies Inc. (CYPH) | $181.04M | 16.5 |
| Veradermics, Incorporated (MANE) | $4.12B | — |
| Relmada Therapeutics, Inc. (RLMD) | $477.25M | -3.3 |
| DiaMedica Therapeutics Inc. (DMAC) | $364.54M | -11.4 |
| NRx Pharmaceuticals, Inc. (NRXP) | $149.37M | -2.0 |
| PDS Biotechnology Corporation (PDSB) | $40.23M | — |
| Longeveron Inc. (LGVN) | — | — |
| RenovoRx, Inc. (RNXT) | $116.36M | — |
| Oramed Pharmaceuticals Inc. (ORMP) | $210.48M | 4.1 |
| Sagimet Biosciences Inc. (SGMT) | $584.26M | -3.7 |
| Sector P/E (Healthcare) | 21.6 |
| Industry P/E (Pharmaceutical Products) | 17.2 |
AKTS overview · AKTS earnings · AKTS financials · AKTS KPIs · AKTS documents · AKTS ownership
Data sourced from U.S. SEC EDGAR filings and market data. Not personalized investment advice.